Response to mycophenolate mofetil therapy for refractory chronic graft-versus-host disease

Alessandro Busca, Franco Locatelli, Filippo Marmont, Ernesta Audisia, Michele Falda

Research output: Contribution to journalArticle

Abstract

Preliminary results of our study suggest that mycophenolate mofetil (MMF) might be a useful treatment in patients who have failed or could not tolerate conventional immunosuppressive therapy for chronic graft-versus-host disease (GVHD). In addition, the favorable toxicity profile and steroid-sparing effect of MMF may be particularly attractive features of this medication.

Original languageEnglish
Pages (from-to)837-839
Number of pages3
JournalHaematologica
Volume88
Issue number7
Publication statusPublished - Jul 1 2003

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Response to mycophenolate mofetil therapy for refractory chronic graft-versus-host disease'. Together they form a unique fingerprint.

  • Cite this